US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
KR850004274A
(ko)
*
|
1983-12-13 |
1985-07-11 |
원본미기재 |
에리트로포이에틴의 제조방법
|
NZ210501A
(en)
*
|
1983-12-13 |
1991-08-27 |
Kirin Amgen Inc |
Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
|
US4703008A
(en)
*
|
1983-12-13 |
1987-10-27 |
Kiren-Amgen, Inc. |
DNA sequences encoding erythropoietin
|
EP0154539A3
(de)
*
|
1984-03-06 |
1986-12-30 |
Eli Lilly And Company |
Rekombinante DNS-Expressionsvektoren und Verfahren für Genexpression
|
GB8522977D0
(en)
*
|
1985-09-17 |
1985-10-23 |
Fujisawa Pharmaceutical Co |
Production of insulin-like growth factor 1
|
IL71691A
(en)
*
|
1984-04-27 |
1991-04-15 |
Yeda Res & Dev |
Production of interferon-ypsilon
|
CA1275954C
(en)
*
|
1984-08-31 |
1990-11-06 |
Hing Cheug Wong |
3'-expression enhancing fragments and method
|
IL80511A0
(en)
*
|
1985-11-05 |
1987-02-27 |
Genetics Inst |
Multiply amplifiable vectors for high level expression of exogenous dna
|
FI870103A
(fi)
*
|
1986-01-13 |
1987-07-14 |
Genex Corp |
Producering av humanserum albumin i en bacillus-stam.
|
CA1297434C
(en)
*
|
1986-04-14 |
1992-03-17 |
Kenji Murakami |
Method of producing peptides, recombinant plasmid for use in the same and animal cells transformed with the same
|
IL82390A0
(en)
*
|
1986-05-02 |
1987-10-30 |
Genentech Inc |
Nucleic acid and methods for the synthesis of novel daf compositions
|
JP2585532B2
(ja)
*
|
1986-05-10 |
1997-02-26 |
三井東圧化学株式会社 |
動物細胞の形質転換体及びそれを得る方法並びにその形質転換体を用いてt−PAを生産する方法
|
AU613876B2
(en)
*
|
1986-10-01 |
1991-08-15 |
Merck & Co., Inc. |
Synthetic genes encoding proteins from plasmid containing eucaryotic secretory signal peptides and process for secreting encoded proteins
|
AU1187588A
(en)
*
|
1987-01-15 |
1988-08-10 |
Codon Genetic Engineering Laboratories |
Tandem gene eukaryotic expression vectors
|
US5013653A
(en)
*
|
1987-03-20 |
1991-05-07 |
Creative Biomolecules, Inc. |
Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
|
US5215896A
(en)
*
|
1987-03-20 |
1993-06-01 |
Creative Biomolecules, Inc. |
Leader sequences for the production of recombinant proteins
|
US5876962A
(en)
*
|
1987-08-12 |
1999-03-02 |
Natural Environment Research Council |
Expression vectors for the synthesis of proteins and plasmid replicons and sequence cassettes for use in constructing such vectors
|
US5648254A
(en)
*
|
1988-01-15 |
1997-07-15 |
Zymogenetics, Inc. |
Co-expression in eukaryotic cells
|
JP2576200B2
(ja)
*
|
1988-03-09 |
1997-01-29 |
味の素株式会社 |
生理活性タンパク質の製造法
|
US4892871A
(en)
*
|
1988-04-12 |
1990-01-09 |
The General Hospital Corporation |
Azido-substituted octopamine agonists and the use thereof to control invertebrate pests
|
AU4036389A
(en)
*
|
1988-07-29 |
1990-03-05 |
Zymogenetics Inc. |
High efficiency translation of polycistronic messages in eucaryotic cells
|
US6451600B1
(en)
*
|
1989-12-22 |
2002-09-17 |
Genzyme Corporation |
Enzymatically active recombinant glucocerebrosidase
|
US5236838A
(en)
*
|
1988-12-23 |
1993-08-17 |
Genzyme Corporation |
Enzymatically active recombinant glucocerebrosidase
|
US20020168750A1
(en)
*
|
1988-12-23 |
2002-11-14 |
James Rasmussen |
Enzymatically active recombinant glucocerebrosidase
|
US5549892A
(en)
*
|
1988-12-23 |
1996-08-27 |
Genzyme Corporation |
Enhanced in vivo uptake of glucocerebrosidase
|
US5545727A
(en)
|
1989-05-10 |
1996-08-13 |
Somatogen, Inc. |
DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
|
SG47987A1
(en)
|
1989-05-10 |
1998-04-17 |
Somatogen Inc |
Production in bacteria and yeast of haemoglobin and analogues thereof
|
US5665543A
(en)
|
1989-07-18 |
1997-09-09 |
Oncogene Science, Inc. |
Method of discovering chemicals capable of functioning as gene expression modulators
|
US5580722A
(en)
*
|
1989-07-18 |
1996-12-03 |
Oncogene Science, Inc. |
Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
|
US6203976B1
(en)
|
1989-07-18 |
2001-03-20 |
Osi Pharmaceuticals, Inc. |
Methods of preparing compositions comprising chemicals capable of transcriptional modulation
|
WO1991001379A1
(en)
*
|
1989-07-18 |
1991-02-07 |
Oncogene Science, Inc. |
Method of transcriptionally modulating gene expression and of discovering chemicals capable of functioning as gene expression modulators
|
US5776502A
(en)
|
1989-07-18 |
1998-07-07 |
Oncogene Science, Inc. |
Methods of transcriptionally modulating gene expression
|
US6475787B1
(en)
*
|
1989-07-28 |
2002-11-05 |
Wyeth |
Method for producing monoclonal antibodies
|
US7247475B2
(en)
*
|
1989-07-28 |
2007-07-24 |
Wyeth |
Method for producing monoclonal antibodies
|
EP0461560B1
(de)
*
|
1990-06-11 |
1998-11-18 |
Toshikazu Nakamura |
Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
|
AU1258292A
(en)
*
|
1991-01-18 |
1992-08-27 |
Oncogene Science, Inc. |
Methods of transcriptionally modulating expression of hematopoietic growth factor genes
|
WO1992013091A1
(en)
*
|
1991-01-18 |
1992-08-06 |
Oncogene Science, Inc. |
Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes
|
AU1469292A
(en)
*
|
1991-01-18 |
1992-08-27 |
Oncogene Science, Inc. |
Methods of transcriptionally modulating expression of growth factor genes and growth factor receptor genes
|
JPH0516500U
(ja)
*
|
1991-08-09 |
1993-03-02 |
富士通テン株式会社 |
車載用機器の取付構造
|
WO1993008842A1
(en)
*
|
1991-11-08 |
1993-05-13 |
Somatogen, Inc. |
Hemoglobins as drug delivery agents
|
WO1994021669A1
(en)
*
|
1993-03-18 |
1994-09-29 |
Medclone, Inc. |
Antigen related to inflammatory diseases
|
US5639940A
(en)
|
1994-03-03 |
1997-06-17 |
Pharmaceutical Proteins Ltd. |
Production of fibrinogen in transgenic animals
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
EP0848755B2
(de)
|
1995-09-08 |
2011-02-09 |
Genentech, Inc. |
Vegf-verwandtes protein
|
US6030945A
(en)
|
1996-01-09 |
2000-02-29 |
Genentech, Inc. |
Apo-2 ligand
|
US6998116B1
(en)
|
1996-01-09 |
2006-02-14 |
Genentech, Inc. |
Apo-2 ligand
|
WO1997037020A1
(en)
|
1996-04-01 |
1997-10-09 |
Genentech, Inc. |
Apo-2li and apo-3 apoptosis polypeptides
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
US6462176B1
(en)
|
1996-09-23 |
2002-10-08 |
Genentech, Inc. |
Apo-3 polypeptide
|
US5990281A
(en)
|
1996-09-30 |
1999-11-23 |
Genentech, Inc. |
Vertebrate smoothened proteins
|
IL129379A
(en)
|
1996-10-16 |
2008-12-29 |
Zymogenetics Inc |
Fibroblast growth factor homologues
|
US6100076A
(en)
|
1997-01-31 |
2000-08-08 |
Genentech, Inc. |
O-fucosyltransferase
|
ATE356212T1
(de)
|
1997-01-31 |
2007-03-15 |
Genentech Inc |
O-fukosyltransferase
|
US6342369B1
(en)
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
DE69838249T3
(de)
|
1997-05-15 |
2012-01-19 |
Genentech, Inc. |
Anti-apo-2 antikörper
|
EP1003856A1
(de)
|
1997-06-05 |
2000-05-31 |
Board of Regents, The University of Texas System |
Apaf-1, menschluches ced-4 homolog, ein aktivator von caspase-3
|
EP1032661A1
(de)
|
1997-06-18 |
2000-09-06 |
Genentech, Inc. |
Apo-2DcR
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
ATE393222T1
(de)
|
1997-09-18 |
2008-05-15 |
Genentech Inc |
Dcr3 polypeptid, ein tnfr homolog
|
ATE424459T1
(de)
|
1997-10-10 |
2009-03-15 |
Genentech Inc |
Apo-3 ligand
|
DE69839942D1
(de)
|
1997-10-29 |
2008-10-09 |
Genentech Inc |
Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1
|
DE69840051D1
(de)
|
1997-10-29 |
2008-11-06 |
Genentech Inc |
Durch wnt-1 induzierbare gene
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
PT1481989E
(pt)
|
1997-11-21 |
2008-08-08 |
Genentech Inc |
Antigénios relacionados com a-33 e suas utilizações farmacológicas
|
CA2318029C
(en)
|
1998-01-15 |
2009-05-19 |
Genentech, Inc. |
Apo-2 ligand
|
US6727079B1
(en)
|
1998-02-25 |
2004-04-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
|
NZ525914A
(en)
|
1998-03-10 |
2004-03-26 |
Genentech Inc |
Novel polypeptides and nucleic acids encoding the same
|
DK2016951T3
(da)
|
1998-03-17 |
2012-09-24 |
Genentech Inc |
VEGF- og BMP1-homologe polypeptider
|
NZ508878A
(en)
|
1998-05-15 |
2003-08-29 |
Genentech Inc |
IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells
|
EP1865061A3
(de)
|
1998-05-15 |
2007-12-19 |
Genentech, Inc. |
IL-17-homologe Polypeptide und ihre therapeutische Verwendung
|
EP3112468A1
(de)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17-homologe polypeptide und therapeutische verwendung davon
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
ES2329741T3
(es)
|
1998-09-23 |
2009-11-30 |
Zymogenetics, Inc. |
Receptor de citoquinas zalpha11.
|
EP1137773B1
(de)
|
1998-12-07 |
2008-08-13 |
ZymoGenetics, Inc. |
Wachstumsfaktor-homologe zvegf-3
|
EP1484338B1
(de)
|
1998-12-22 |
2007-02-07 |
Genentech, Inc. |
Verfahren und Zusammensetzung zur Hemmung des neoplastischen Zellwachstums
|
JP5456222B2
(ja)
|
1998-12-23 |
2014-03-26 |
ジェネンテック, インコーポレイテッド |
Il−1関連ポリペプチド
|
ATE453712T1
(de)
|
1999-01-07 |
2010-01-15 |
Zymogenetics Inc |
Verfahren zur therapeutischen verwendung von löslichen rezeptoren br43x2
|
US7833529B1
(en)
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
HU229148B1
(en)
|
1999-03-09 |
2013-09-30 |
Zymogenetics Inc Seattle |
Human cytokine as ligand of the zalpha receptor and uses thereof
|
US6696424B1
(en)
|
1999-05-28 |
2004-02-24 |
Vical Incorporated |
Cytofectin dimers and methods of use thereof
|
EP1953173B1
(de)
|
1999-06-15 |
2009-11-18 |
Genentech, Inc. |
Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
|
CN100526463C
(zh)
|
1999-06-28 |
2009-08-12 |
杰南技术公司 |
利用二价金属离子制备Apo-2配体的方法
|
US20050005310A1
(en)
*
|
1999-07-12 |
2005-01-06 |
Genentech, Inc. |
Expression vectors and methods
|
US20040235715A1
(en)
*
|
1999-11-12 |
2004-11-25 |
Bayer Corporation |
Method of producing glycosylated bikunin
|
EP1686134A3
(de)
|
1999-12-01 |
2006-08-09 |
Genentech, Inc. |
Ausgeschiedene und Transmembran-Polypeptide und dafür kodierende Nukleinsäuren
|
CA2395369C
(en)
|
1999-12-23 |
2014-07-08 |
Zymogenetics, Inc. |
Cytokine zcyto18
|
EP1897945B1
(de)
|
1999-12-23 |
2012-01-18 |
Genentech, Inc. |
IL-17-homologe Polypeptide und ihre therapeutische Verwendung
|
ATE424457T1
(de)
|
2000-01-13 |
2009-03-15 |
Genentech Inc |
Menschliche stra6 polypeptide
|
IL150755A0
(en)
|
2000-02-16 |
2003-02-12 |
Genentech Inc |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
WO2001070672A2
(en)
|
2000-03-23 |
2001-09-27 |
Elan Pharmaceuticals, Inc. |
Compounds and methods to treat alzheimer's disease
|
EP2792747A1
(de)
|
2000-06-23 |
2014-10-22 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
|
EP2168980A1
(de)
|
2000-06-23 |
2010-03-31 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
|
JP2004501628A
(ja)
|
2000-06-26 |
2004-01-22 |
ザイモジェネティクス,インコーポレイティド |
サイトカイン受容体zcytor17
|
EP1939293A3
(de)
|
2000-06-30 |
2008-07-09 |
ZymoGenetics, Inc. |
Interferonähnliches Protein ZCYTO21
|
ATE314343T1
(de)
|
2000-06-30 |
2006-01-15 |
Elan Pharm Inc |
Verbindungen zur behandlung der alzheimerischen krankheit
|
US20020106729A1
(en)
|
2000-07-03 |
2002-08-08 |
Bleck Gregory T. |
Expression vectors
|
AU2001284948A1
(en)
|
2000-08-15 |
2002-02-25 |
Board Of Trustees Of The University Of Illinois |
Animals expressing exogenous igf-i in their milk
|
ATE412009T1
(de)
|
2000-08-24 |
2008-11-15 |
Genentech Inc |
Methode zur inhibierung von il-22 induziertem pap1
|
EP1944317A3
(de)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
|
IL154520A0
(en)
|
2000-09-13 |
2003-09-17 |
Novo Nordisk As |
Human coagulation factor vii variants
|
US6673580B2
(en)
|
2000-10-27 |
2004-01-06 |
Genentech, Inc. |
Identification and modification of immunodominant epitopes in polypeptides
|
MXPA03008590A
(es)
|
2001-03-22 |
2003-12-08 |
Novo Nordisk Healthcare Ag |
Derivados del factor vii de coagulacion.
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
CA2633413C
(en)
|
2001-06-20 |
2012-08-21 |
Genentech, Inc. |
Antibodies against tumor-associated antigenic target (tat) polypeptides
|
BR0212070A
(pt)
|
2001-08-29 |
2004-09-28 |
Genentech Inc |
ácidos nucléicos e polipeptìdeos bv8 com atividade mitogênica
|
ATE516042T1
(de)
|
2001-09-18 |
2011-07-15 |
Genentech Inc |
Zusammensetzungen und verfahren zur behandlung und diagnose von tumoren
|
CN1602354A
(zh)
|
2001-09-27 |
2005-03-30 |
诺和诺德医疗保健公司 |
人凝血因子ⅶ多肽
|
WO2003029420A2
(en)
|
2001-10-02 |
2003-04-10 |
Genentech, Inc. |
Apo-2 ligand variants and uses thereof
|
IL161251A0
(en)
|
2001-10-10 |
2004-09-27 |
Neose Technologies Inc |
Remodeling and glycoconjugation of peptides
|
DK2279753T3
(en)
|
2001-10-10 |
2015-11-23 |
Novo Nordisk As |
The conversion of peptides and glycokonjugering
|
CA2465156C
(en)
|
2001-11-05 |
2011-10-18 |
Zymogenetics, Inc. |
Il-21 antagonists
|
EP1450847B1
(de)
|
2001-11-13 |
2010-09-29 |
Genentech, Inc. |
Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung
|
US20030157641A1
(en)
*
|
2001-11-16 |
2003-08-21 |
Idec Pharmaceuticals Corporation |
Polycistronic expression of antibodies
|
CN1585822A
(zh)
|
2001-11-16 |
2005-02-23 |
拜奥根Idec公司 |
抗体的多顺反子表达
|
EP2067472A1
(de)
|
2002-01-02 |
2009-06-10 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
PT1576112E
(pt)
|
2002-01-18 |
2012-05-25 |
Zymogenetics Inc |
Multímeros de receptor de citocina zcytor17
|
ES2351678T3
(es)
|
2002-01-18 |
2011-02-09 |
Zymogenetics, Inc. |
Ligando de citocina para el tratamiento de asma e hiper-sensibilidad de las vías respiratorias .
|
EP2388265A1
(de)
|
2002-02-22 |
2011-11-23 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
|
CA2477249A1
(en)
|
2002-02-25 |
2003-09-04 |
Genentech, Inc. |
Novel type-1 cytokine receptor glm-r
|
US20040038304A1
(en)
|
2002-03-28 |
2004-02-26 |
Gala Design, Inc. |
Antibody libraries
|
US7384738B2
(en)
|
2002-03-28 |
2008-06-10 |
Bremel Robert D |
Retrovirus-based genomic screening
|
AU2003230874A1
(en)
|
2002-04-16 |
2003-11-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
DE60335536D1
(de)
|
2002-04-19 |
2011-02-10 |
Bristol Myers Squibb Co |
Verfahren zum nachweis oder zur modulierung der wechselwirkung eines cytokinrezeptors mit seinem ligand
|
EP2305710A3
(de)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetische Antikörperphagenbibliotheken
|
WO2003103725A1
(en)
|
2002-06-07 |
2003-12-18 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2004001009A2
(en)
|
2002-06-24 |
2003-12-31 |
Genentech, Inc. |
Apo-2 ligand/trail variants and uses thereof
|
AU2003247806B2
(en)
|
2002-07-08 |
2009-11-12 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
AU2003270439B2
(en)
|
2002-09-11 |
2009-09-24 |
Genentech, Inc. |
Novel composition and methods for the treatment of immune related diseases
|
EP2116551A1
(de)
|
2002-09-11 |
2009-11-11 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
|
EP2444409A2
(de)
|
2002-09-16 |
2012-04-25 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
|
AU2003279084A1
(en)
|
2002-09-25 |
2004-04-19 |
Genentech, Inc. |
Novel compositions and methods for the treatment of psoriasis
|
EP2322200A3
(de)
|
2002-10-29 |
2011-07-27 |
Genentech, Inc. |
Gestaltungen und Methoden für die Behandlung von immune verwandte Krankheiten
|
CA2503748A1
(en)
|
2002-11-08 |
2004-05-27 |
Genentech, Inc. |
Compositions and methods for the treatment of natural killer cell related diseases
|
EP1567658A2
(de)
*
|
2002-11-14 |
2005-08-31 |
Genentech, Inc. |
Intronfusionskonstrukt undverwendungsverfahren zur selektion hochexprimierender produktionszellinien
|
WO2004047728A2
(en)
|
2002-11-26 |
2004-06-10 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
KR101118340B1
(ko)
|
2003-03-12 |
2012-04-12 |
제넨테크, 인크. |
조혈을 촉진하기 위한 bv8 및(또는) eg-vegf의용도
|
MXPA05009770A
(es)
|
2003-03-18 |
2005-11-17 |
Novo Nordisk Healthcare Ag |
Metodo para la produccion de serina proteasas que contienen residuos de gla.
|
CA2519241A1
(en)
|
2003-04-01 |
2004-11-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
AU2004229335C1
(en)
|
2003-04-04 |
2010-06-17 |
Genentech, Inc. |
High concentration antibody and protein formulations
|
WO2004092329A2
(en)
*
|
2003-04-08 |
2004-10-28 |
Galenica Pharmaceuticals, Inc. |
Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines
|
MXPA05010773A
(es)
|
2003-04-09 |
2005-12-12 |
Neose Technologies Inc |
Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
PL2298347T3
(pl)
|
2003-05-06 |
2016-03-31 |
Bioverativ Therapeutics Inc |
Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
|
US20050014932A1
(en)
|
2003-05-15 |
2005-01-20 |
Iogenetics, Llc |
Targeted biocides
|
ES2538469T3
(es)
|
2003-06-05 |
2015-06-22 |
Genentech, Inc. |
Terapia de combinación para trastornos de células B
|
DK1636260T3
(da)
|
2003-06-10 |
2009-06-22 |
Biogen Idec Inc |
Forbedret udskillelse af Neublastin
|
KR100835786B1
(ko)
|
2003-07-08 |
2008-06-09 |
제넨테크, 인크. |
Il-17a/f 이종 폴리펩티드 및 그의 치료 용도
|
ES2303132T3
(es)
|
2003-08-07 |
2008-08-01 |
Zymogenetics, Inc. |
Preparaciones homogeneas de il-29.
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
JP4751326B2
(ja)
|
2003-09-04 |
2011-08-17 |
メダレックス インコーポレイテッド |
発現ベクター
|
ATE547519T1
(de)
|
2003-09-09 |
2012-03-15 |
Novo Nordisk Healthcare Ag |
Gerinnungsfaktor-vii-polypeptide
|
CA2747871C
(en)
|
2003-11-17 |
2018-04-10 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
EP1711610A2
(de)
*
|
2004-01-28 |
2006-10-18 |
Syntonix Pharmaceuticals, Inc. |
Heterodimere follikel-stimulierendes-hormon-fc (fsh-fc)-fusionsproteine zur behandlung von unfruchtbarkeit
|
WO2005087810A2
(en)
|
2004-03-08 |
2005-09-22 |
Zymogenetics, Inc. |
Dimeric fusion proteins and materials and methods for producing them
|
WO2006014928A1
(en)
|
2004-07-26 |
2006-02-09 |
Genentech, Inc. |
Methods and compositions for modulating hepatocyte growth factor activation
|
WO2006012644A2
(en)
|
2004-07-29 |
2006-02-02 |
Zymogenetics, Inc. |
Use of il-28 and il-29 to treat cancer
|
TWI384069B
(zh)
|
2004-08-27 |
2013-02-01 |
Pfizer Ireland Pharmaceuticals |
多胜肽之製法
|
US7300773B2
(en)
|
2004-08-27 |
2007-11-27 |
Wyeth Research Ireland Limited |
Production of TNFR-Ig
|
TWI374935B
(en)
|
2004-08-27 |
2012-10-21 |
Pfizer Ireland Pharmaceuticals |
Production of α-abeta
|
EP1891112A1
(de)
|
2005-05-12 |
2008-02-27 |
ZymoGenetics, Inc. |
Verfahren zur anwendung von pnkp 30, einem mitglied der b7-familie, für die modulierung des immunsystems
|
US7858843B2
(en)
|
2005-06-06 |
2010-12-28 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
JP5118037B2
(ja)
|
2005-08-09 |
2013-01-16 |
ザイモジェネティクス, インコーポレイテッド |
Taci融合分子を用いた異常細胞増殖の処置及び予防のための方法
|
ZA200801354B
(en)
*
|
2005-08-09 |
2009-08-26 |
Ares Trading Sa |
Methods for treating B-cell malignancies using TACI-lg fusion molecule
|
US7931902B2
(en)
|
2005-08-15 |
2011-04-26 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
US20090055942A1
(en)
|
2005-09-14 |
2009-02-26 |
Novo Nordisk Healthcare A/G |
Human Coagulation Factor VII Polypeptides
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
CA2630432A1
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
ES2503365T5
(es)
|
2005-12-21 |
2017-10-31 |
Cnj Holdings, Inc |
Método para producir proteínas dependientes de vitamina K biológicamente activas por métodos recombinantes
|
EP2050335A1
(de)
|
2006-02-17 |
2009-04-22 |
Genentech, Inc. |
Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
|
TW200745163A
(en)
*
|
2006-02-17 |
2007-12-16 |
Syntonix Pharmaceuticals Inc |
Peptides that block the binding of IgG to FcRn
|
RU2008139428A
(ru)
|
2006-03-06 |
2010-05-20 |
Хьюмэджин, Инк. (Us) |
Способ получения рекомбинантного тромбина и фибриногена человека
|
US7566565B2
(en)
|
2006-03-24 |
2009-07-28 |
Syntonix Pharmaceuticals, Inc. |
PC5 as a factor IX propeptide processing enzyme
|
EP2614839A3
(de)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Verfahren zur Verwendung von BOC/CDO zur Modulation der Hedgehog-Signalisierung
|
US20090288176A1
(en)
|
2006-04-19 |
2009-11-19 |
Genentech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
EP2027291A2
(de)
|
2006-04-27 |
2009-02-25 |
Pikamab, Inc. |
Verfahren und zusammensetzungen für antikörpertherapie
|
BRPI0711823A2
(pt)
*
|
2006-05-15 |
2012-01-17 |
Ares Trading Sa |
métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
|
JP2009537609A
(ja)
|
2006-05-24 |
2009-10-29 |
ノボ ノルディスク ヘルス ケア アーゲー |
延長されたfixアナログ及び誘導体
|
WO2008005847A2
(en)
|
2006-06-30 |
2008-01-10 |
The Regents Of The University Of Michigan |
Method of producing factor viii proteins by recombinant methods
|
PT2495307T
(pt)
|
2006-07-13 |
2018-05-10 |
Wyeth Llc |
Produção do fator ix de coagulação com padrão melhorado de glicosilação
|
NZ576445A
(en)
|
2006-11-02 |
2012-03-30 |
Daniel J Capon |
Hybrid immunoglobulins with moving parts
|
WO2008066658A2
(en)
|
2006-11-03 |
2008-06-05 |
The Trustees Of Princeton University |
Engineered cellular pathways for programmed autoregulation of differentiation
|
JP5401319B2
(ja)
|
2006-11-03 |
2014-01-29 |
ワイス・エルエルシー |
細胞培養における解糖阻害物質
|
BRPI0807635A2
(pt)
|
2007-02-22 |
2014-06-03 |
Genentech Inc |
Métodos para detecção de doença inflamatória intestinal
|
US9012180B2
(en)
|
2007-03-02 |
2015-04-21 |
Wyeth Llc |
Use of copper and glutamate in cell culture for production of polypeptides
|
EP2517714A1
(de)
|
2007-04-26 |
2012-10-31 |
Inspiration Biopharmaceuticals, Inc. |
Rekombinante Vitamin-K-abhängige Proteine mit hohem Sialsäuregehalt und Verfahren zu ihrer Herstellung
|
EP2474557B1
(de)
|
2007-07-16 |
2014-08-20 |
Genentech, Inc. |
Anti-CD79b Antikörper und Immunkonjugate sowie Verwendungsverfahren
|
PE20140625A1
(es)
|
2007-07-16 |
2014-05-29 |
Genentech Inc |
ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
|
CN101361968B
(zh)
|
2007-08-06 |
2011-08-03 |
健能隆医药技术(上海)有限公司 |
白介素-22在治疗脂肪肝中的应用
|
EP2203471A2
(de)
*
|
2007-08-09 |
2010-07-07 |
Syntonix Pharmaceuticals, Inc. |
Immunmodulatorische peptide
|
EP2200631A1
(de)
|
2007-10-16 |
2010-06-30 |
Zymogenetics, Inc. |
Kombination aus blys-hemmung und anti-cd20-wirkstoffen zur behandlung von autoimmunerkrankungen
|
RU2553566C2
(ru)
|
2008-01-31 |
2015-06-20 |
Дженентек, Инк. |
АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
ES2456296T3
(es)
|
2008-03-27 |
2014-04-21 |
Zymogenetics, Inc. |
Composiciones y procedimientos para inhibir PDGFR beta y VEGF-A
|
CA2719189C
(en)
|
2008-04-09 |
2020-08-04 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
US8658766B2
(en)
|
2008-06-27 |
2014-02-25 |
Zymogenetics, Inc. |
Soluble hybrid Fcγ receptors and related methods
|
US20100048488A1
(en)
*
|
2008-08-01 |
2010-02-25 |
Syntonix Pharmaceuticals, Inc. |
Immunomodulatory peptides
|
MX2011002638A
(es)
|
2008-09-15 |
2011-04-05 |
Genentech Inc |
Composiciones y metodos para regular osmolaridad celular.
|
US9702877B2
(en)
|
2008-10-31 |
2017-07-11 |
Quest Diagnostics Investments Incorporated |
BCR-ABL variants
|
KR101655492B1
(ko)
*
|
2008-12-22 |
2016-09-07 |
국립대학법인 홋가이도 다이가쿠 |
동물세포를 사용해서 외래유전자 유래 단백질을 대량으로 생산하기 위한 발현 벡터, 및 그의 이용
|
CA2748314C
(en)
|
2009-02-03 |
2018-10-02 |
Amunix Operating Inc. |
Extended recombinant polypeptides and compositions comprising same
|
AU2010236787A1
(en)
|
2009-04-01 |
2011-11-10 |
Genentech, Inc. |
Anti-FcRH5 antibodies and immunoconjugates and methods of use
|
CA2767755C
(en)
|
2009-07-17 |
2021-10-12 |
Rigshospitalet |
Inhibitors of complement activation
|
KR20180114966A
(ko)
|
2009-08-11 |
2018-10-19 |
제넨테크, 인크. |
글루타민-비함유 세포 배양 배지에서의 단백질의 생성
|
WO2011028229A1
(en)
|
2009-08-24 |
2011-03-10 |
Amunix Operating Inc. |
Coagulation factor ix compositions and methods of making and using same
|
WO2011041308A1
(en)
|
2009-09-30 |
2011-04-07 |
Quest Diagnostics Investments Incorporated |
Bcr-abl truncation mutations
|
MX2012004303A
(es)
|
2009-10-15 |
2012-06-25 |
Genentech Inc |
Factores de crecimiento de fibroblasto quimericos con especificacion de receptor alterada.
|
KR20120105446A
(ko)
|
2009-10-22 |
2012-09-25 |
제넨테크, 인크. |
대식세포-자극 단백질의 헵신 활성화를 조정하기 위한 방법 및 조성물
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
EP2494040B1
(de)
|
2009-10-30 |
2018-08-29 |
Aptevo BioTherapeutics LLC |
Verfahren zur herstellung rekombinanter vitamin-k-abhängiger proteine
|
AR078986A1
(es)
|
2009-11-12 |
2011-12-14 |
Genentech Inc |
Un metodo para promover la densidad de espinas dendriticas
|
NZ599707A
(en)
|
2009-11-30 |
2014-07-25 |
Genentech Inc |
Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
|
WO2011071957A1
(en)
|
2009-12-07 |
2011-06-16 |
Sea Lane Biotechnologies, Llc |
Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
|
WO2011106297A2
(en)
|
2010-02-23 |
2011-09-01 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2011107591A1
(en)
|
2010-03-05 |
2011-09-09 |
Rigshospitalet |
Chimeric inhibitor molecules of complement activation
|
CN107090045A
(zh)
|
2010-05-03 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
用于肿瘤诊断和治疗的组合物和方法
|
CA2802017A1
(en)
|
2010-06-09 |
2011-12-15 |
Zymogenetics, Inc. |
Dimeric vstm3 fusion proteins and related compositions and methods
|
ES2690760T3
(es)
|
2010-06-25 |
2018-11-22 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Polipéptido de flagelina como agonista de TLR5 para su uso en el tratamiento de infecciones de las vías respiratorias
|
US9611310B2
(en)
|
2010-07-09 |
2017-04-04 |
Bioverativ Therapeutics Inc. |
Systems for factor VIII processing and methods thereof
|
CA2807607A1
(en)
|
2010-08-20 |
2012-02-23 |
Wyeth Llc |
Cell culture of growth factor-free adapted cells
|
CN102380091A
(zh)
|
2010-08-31 |
2012-03-21 |
健能隆医药技术(上海)有限公司 |
白介素-22在治疗病毒性肝炎中的应用
|
EP2616481A4
(de)
|
2010-09-15 |
2014-04-02 |
Aligna Technologies Inc |
Bioproduktion aromatischer chemikalien aus von lignin abgeleiteten verbindungen
|
US8603740B2
(en)
|
2010-12-29 |
2013-12-10 |
Quest Diagnostics Investments Incorporated |
BCR-ABL1 splice variants and uses thereof
|
WO2012101509A2
(en)
|
2011-01-28 |
2012-08-02 |
Sanofi Pasteur Sa |
Immunological compositions against hiv
|
JP2014515598A
(ja)
|
2011-03-10 |
2014-07-03 |
エイチシーオー アンティボディ, インク. |
二重特異性三鎖抗体様分子
|
CA2834776A1
(en)
|
2011-05-03 |
2012-11-08 |
Genentech, Inc. |
Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
|
ES2687651T3
(es)
|
2011-09-12 |
2018-10-26 |
Amunix Operating Inc. |
Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
|
CA2852021C
(en)
|
2011-10-21 |
2018-08-28 |
Pfizer Inc. |
Addition of iron to improve cell culture
|
US8748097B1
(en)
|
2011-12-02 |
2014-06-10 |
President And Fellows Of Harvard College |
Identification of agents for treating calcium disorders and uses thereof
|
PT2804623T
(pt)
|
2012-01-12 |
2019-11-18 |
Bioverativ Therapeutics Inc |
Polipéptidos quiméricos do fator viii e suas utilizações
|
EP3597764A3
(de)
|
2012-02-01 |
2020-05-06 |
SGI-DNA, Inc. |
Material und verfahren zur synthese von fehlerminimierten nukleinsäuremolekülen
|
JP6517018B2
(ja)
|
2012-02-09 |
2019-05-22 |
ヴァー2・ファーマシューティカルズ・アンパルトセルスカブVAR2 Pharmaceuticals ApS |
コンドロイチン硫酸グリカンのターゲティング
|
CA2864126A1
(en)
|
2012-02-15 |
2013-08-22 |
Biogen Idec Ma Inc. |
Recombinant factor viii proteins
|
LT3564260T
(lt)
|
2012-02-15 |
2023-01-10 |
Bioverativ Therapeutics Inc. |
Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
|
US9493744B2
(en)
|
2012-06-20 |
2016-11-15 |
Genentech, Inc. |
Methods for viral inactivation and other adventitious agents
|
US20130281355A1
(en)
|
2012-04-24 |
2013-10-24 |
Genentech, Inc. |
Cell culture compositions and methods for polypeptide production
|
PT2841087T
(pt)
|
2012-04-27 |
2017-11-27 |
Us Health |
Antagonistas de fator de crescimento endotelial vascular e métodos para utilização dos mesmos
|
JP6279466B2
(ja)
|
2012-04-27 |
2018-02-14 |
Jcrファーマ株式会社 |
新規な発現ベクター
|
BR112015000267B1
(pt)
|
2012-07-11 |
2023-01-24 |
Bioverativ Therapeutics Inc. |
Proteínas quiméricas, e composição farmacêutica
|
CN104704118A
(zh)
|
2012-10-15 |
2015-06-10 |
诺和诺德保健Ag(股份有限公司) |
凝血因子vii多肽
|
EP2922871B1
(de)
|
2012-11-20 |
2019-06-19 |
The University of North Carolina At Chapel Hill |
Verfahren und zusammensetzungen für modifizierte faktor-ix-proteine
|
WO2014115087A2
(en)
|
2013-01-22 |
2014-07-31 |
Cencor Biotech Ltd. |
A method for the preparation of recombinant human prothrombin and fibrinogen
|
ES2676023T3
(es)
|
2013-03-15 |
2018-07-16 |
F. Hoffmann-La Roche Ag |
Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
|
CA2906175C
(en)
|
2013-03-15 |
2022-12-13 |
Daniel J. Capon |
Hybrid immunoglobulin containing non-peptidyl linkage
|
SG11201505926VA
(en)
|
2013-03-15 |
2015-09-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
NZ713904A
(en)
|
2013-06-28 |
2022-02-25 |
Bioverativ Therapeutics Inc |
Thrombin cleavable linker with xten and its uses thereof
|
EP3875106A1
(de)
|
2013-08-08 |
2021-09-08 |
Bioverativ Therapeutics Inc. |
Reinigung von chimären fviii-molekülen
|
TW202003554A
(zh)
|
2013-08-14 |
2020-01-16 |
美商百歐維拉提夫治療公司 |
因子viii-xten融合物及其用途
|
CN104623637A
(zh)
|
2013-11-07 |
2015-05-20 |
健能隆医药技术(上海)有限公司 |
Il-22二聚体在制备静脉注射药物中的应用
|
RU2707951C1
(ru)
|
2013-11-15 |
2019-12-02 |
Дженентек, Инк. |
Способы инактивации вируса с использованием экологичных детергентов
|
CN116621991A
(zh)
|
2014-01-10 |
2023-08-22 |
比奥贝拉蒂治疗公司 |
因子viii嵌合蛋白及其用途
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
LT3116486T
(lt)
|
2014-03-14 |
2020-04-10 |
Biomolecular Holdings Llc |
Hibridinis imunoglobulinas, turintis nepetidilinę jungtį
|
WO2015140708A1
(en)
|
2014-03-19 |
2015-09-24 |
Pfizer Inc. |
Method of cell culture
|
US10954282B2
(en)
|
2014-12-09 |
2021-03-23 |
Wentao Zhang |
NBP158 and uses thereof
|
WO2016127057A1
(en)
|
2015-02-06 |
2016-08-11 |
The University Of North Carolina At Chapel Hill |
Optimized human clotting factor viii gene expression cassettes and their use
|
RU2017145002A
(ru)
|
2015-05-22 |
2019-06-24 |
Цсл Беринг Ленгнау Аг |
Способы получения модифицированного фактора фон виллебранда
|
DK3297656T3
(da)
|
2015-05-22 |
2020-03-09 |
CSL Behring Lengnau AG |
Trunkeret von Willebrand Faktor polypeptider til behandling af hæmofili
|
EA201890423A1
(ru)
|
2015-08-03 |
2018-07-31 |
Биовератив Терапьютикс Инк. |
Слитые белки фактора ix, способы их получения и применения
|
AU2016321146C1
(en)
|
2015-09-08 |
2021-10-28 |
Theripion, Inc. |
ApoA-1 fusion polypeptides and related compositions and methods
|
EP3184149A1
(de)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Lösliches glycoprotein v zur behandlung von thrombose-erkrankungen
|
JP6851381B6
(ja)
|
2016-01-07 |
2021-04-21 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
変異切断型フォンウィルブランド因子
|
EP3196295A1
(de)
|
2016-01-25 |
2017-07-26 |
Albert-Ludwigs-Universität Freiburg |
Verfahren zur herstellung von nierenzellen aus fibroblasten
|
JP7253923B2
(ja)
|
2016-04-05 |
2023-04-07 |
ファイザー・インク |
細胞培養プロセス
|
EP3442562B1
(de)
|
2016-04-15 |
2022-09-21 |
Evive Biotechnology (Shanghai) Ltd |
Ein il-22-dimer zur verwendung in der behandlung der nekrotisierenden enterokolitis
|
TW201828975A
(zh)
|
2016-11-11 |
2018-08-16 |
瑞士商Csl貝林重組技能公司 |
用於治療血友病之截短型類血友病因子(von Willebrand factor)多肽類
|
JP2020504082A
(ja)
|
2016-11-11 |
2020-02-06 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド
|
WO2018136163A2
(en)
|
2016-12-09 |
2018-07-26 |
Theripion, Inc. |
Tandem apoa-1 fusion polypeptides
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
EP3596206A1
(de)
|
2017-03-16 |
2020-01-22 |
Pfizer Inc |
Tyrosinprototrophie
|
EP4230649A3
(de)
|
2017-04-25 |
2023-10-25 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antikörper und verfahren zur diagnose und behandlung von epstein barr-virusinfektion
|
WO2018234518A1
(en)
|
2017-06-22 |
2018-12-27 |
CSL Behring Lengnau AG |
MODULATION OF IMMUNOGENICITY OF FVIII BY VWF TRONQUÉ
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
|
IL272103B1
(en)
|
2017-07-20 |
2024-06-01 |
Aptevo Res & Development Llc |
Antigen-binding proteins that bind to 5T4 and 4-1BB, as well as compositions and methods for treating cancer related to them
|
KR102476887B1
(ko)
|
2017-12-20 |
2022-12-13 |
하버 바이오메드 (상하이) 컴퍼니 리미티드 |
Ctla-4에 결합하는 항체 및 이의 용도
|
US10150801B1
(en)
|
2017-12-27 |
2018-12-11 |
Imunami Laboratories Pte. Ltd. |
Recombinant polypeptides and methods of use thereof
|
WO2019132765A1
(en)
|
2017-12-27 |
2019-07-04 |
Imunami Laboratories Pte. Ltd. |
Recombinant polypeptides and methods of use thereof
|
KR20200115546A
(ko)
|
2018-01-26 |
2020-10-07 |
제넨테크, 인크. |
IL-22 Fc 융합 단백질 및 사용 방법
|
LT3743088T
(lt)
|
2018-01-26 |
2022-12-27 |
F. Hoffmann-La Roche Ag |
Il-22 fc kompozicijos ir jų naudojimo būdai
|
AU2019226085A1
(en)
|
2018-02-21 |
2020-09-17 |
Genentech, Inc. |
Dosing for treatment with IL-22 Fc fusion proteins
|
EP3788071A1
(de)
|
2018-05-02 |
2021-03-10 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Antikörper und verfahren zur diagnose, prävention und behandlung von epstein-barr-virusinfektion
|
SG11202010767SA
(en)
|
2018-05-18 |
2020-11-27 |
Bioverativ Therapeutics Inc |
Methods of treating hemophilia a
|
US20210278406A1
(en)
|
2018-07-13 |
2021-09-09 |
Varct Diagnostic Aps |
Isolation of circulating cells of fetal origin using recombinant malaria protein var2csa
|
CA3121884A1
(en)
|
2018-12-06 |
2020-06-11 |
Pfizer Inc. |
Cells with reduced inhibitor production and methods of use thereof
|
CN114072420B
(zh)
|
2019-07-04 |
2024-06-11 |
康诺贝林伦瑙有限公司 |
用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
|
EP4021512A1
(de)
|
2019-08-26 |
2022-07-06 |
Imunami Laboratories Pte. Ltd. |
Rekombinante polypeptide und verfahren zur verwendung davon
|
US10675332B1
(en)
|
2019-08-26 |
2020-06-09 |
Imunami Laboratories Pte. Ltd. |
Recombinant polypeptides and methods of use thereof
|
JP2023500953A
(ja)
|
2019-11-11 |
2023-01-11 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
第viii因子に対する寛容を誘導するためのポリペプチド
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
WO2021262081A1
(en)
|
2020-06-22 |
2021-12-30 |
Imunami Laboratories Pte. Ltd. |
Recombinant polypeptides and combinations for use in the treatment of cancer
|
WO2022023972A1
(en)
|
2020-07-30 |
2022-02-03 |
Pfizer Inc. |
Cells having gene duplications and uses thereof
|
AU2021338361A1
(en)
|
2020-09-03 |
2023-04-06 |
Chen, Irvin S.Y |
Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
|
JP2022060169A
(ja)
|
2020-10-02 |
2022-04-14 |
ファイザー・インク |
Rsv fタンパク質生産のための細胞培養工程
|
WO2022178090A2
(en)
|
2021-02-19 |
2022-08-25 |
Theripion, Inc. |
Dnase fusion polypeptides and related compositions and methods
|
JP2022184798A
(ja)
|
2021-06-01 |
2022-12-13 |
ファイザー・インク |
sFGFR3ポリペプチドを生産するための細胞培養方法
|
CA3227875A1
(en)
|
2021-08-02 |
2023-02-09 |
Pfizer Inc. |
Improved expression vectors and uses thereof
|
WO2023079058A1
(en)
|
2021-11-05 |
2023-05-11 |
Yokogawa Insilico Biotechnology Gmbh |
Cell culture with reduced production of lactate
|
CN116554303A
(zh)
|
2022-01-30 |
2023-08-08 |
斯莱普泰(上海)生物医药科技有限公司 |
载脂蛋白E的C端片段及其在抑制γ分泌酶酶活中的应用
|
WO2023148598A1
(en)
|
2022-02-02 |
2023-08-10 |
Pfizer Inc. |
Cysteine prototrophy
|
WO2024148328A2
(en)
|
2023-01-06 |
2024-07-11 |
Aptevo Research And Development Llc |
Bispecific pd-l1 and cd40 binding molecules and uses thereof
|